Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-15
2010-06-22
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S302100, C548S303100, C548S306400
Reexamination Certificate
active
07741355
ABSTRACT:
Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.
REFERENCES:
patent: 3821221 (1974-06-01), Podesva et al.
patent: 4020153 (1977-04-01), Rowsell et al.
patent: 4150052 (1979-04-01), Watson et al.
patent: 4153679 (1979-05-01), Rowsell et al.
patent: 4248859 (1981-02-01), Rowsell et al.
patent: 4296093 (1981-10-01), Rowsell et al.
patent: 4459425 (1984-07-01), Amano et al.
patent: 5266592 (1993-11-01), Grub et al.
patent: 5756857 (1998-05-01), Kuribayashi et al.
patent: 6328982 (2001-12-01), Shiroyama et al.
patent: 6497859 (2002-12-01), Zanone et al.
patent: 2004/0001801 (2004-01-01), Madison
patent: 2005/0054651 (2005-03-01), Natarajan
patent: 2005/0084447 (2005-04-01), Wei
patent: 2007/0232603 (2007-10-01), Moreno et al.
patent: 1 121 927 (2001-08-01), None
patent: 11 57 617 (2001-11-01), None
patent: 2000-247910 (2000-09-01), None
patent: 93/23005 (1993-11-01), None
patent: 93/25177 (1993-12-01), None
patent: 2002/095007 (2002-11-01), None
patent: 2002/095007 (2002-11-01), None
patent: 2005/070460 (2004-08-01), None
patent: 2005/002582 (2005-01-01), None
patent: 2005/002582 (2005-01-01), None
patent: WO 2005/0025852 (2005-01-01), None
patent: 2005/020897 (2005-03-01), None
patent: 2005/020897 (2005-03-01), None
patent: 2005/070460 (2005-08-01), None
patent: 2007/095340 (2007-08-01), None
patent: 2007/095340 (2007-08-01), None
Patani, et al. Bioisoterism: A Rational Approach in Drug Design, Chem. Rev. 1996, 96, pp. 3147-3176, especially p. 3149.
Bardyshev, I.I. et al., “Synthesis and pesticide activity of some amino derivatives of terpenoids,”Vesti Akademii Navuk BSSR, Seryya Khimichnykh Navuk, 1984, vol. 4, pp. 89-91, Abstract only.
Barren III, R.J. et al., “Monoclonal Antibody 7E11.C5 Staining of Viable LNCaP Cells,”The Prostate, 1997, vol. 30, pp. 65-68.
Barry, M.J. et al., “Measuring the Symptoms and Health Impact of Benign Prostatic Hyperplasia and its Treatments,”Benign Prostatic Hyperplasia, 5th International Consultation on Benign Prostatic Hyperplasia(BPH), C. Chatelain et al., eds., Jun. 25-28, 2000, Paris, Health Publication, Ltd, 2001, pp. 203-225.
Beck, B. et al., “Prospects for prostate cancer imaging and therapy using high-affinity TRPM8 activators,”Cell Calcium, 2007, vol. 41, pp. 285-294.
Bödding, M. et al., “Characterisation of TRPM8 as a pharmacophore receptor,”Cell Calcium, 2007, vol. 42, pp. 618-628.
Clapham, D.E. et al., “The TRP Ion Channel Family,”Nature Reviews, Jun. 2001, vol. 2, pp. 387-396.
Clapham, D.E., “HotandCold TRP Ion Channels,”Science, Mar. 22, 2002, vol. 295, pp. 2228-2229.
Clapham, D.E. et al.,Transient Receptor Potential Channels, The IUPHAR Ion Channel Compendium, IUPHAR Media, Communications Division of the International Union of Pharmacology, 2002, Royston: United Kingdom, pp. 209-235.
Correale, P. et al., “Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide,”The Journal of Immunology, 1998, vol. 161, pp. 3186-3194.
Costello, L.C. et al., “Citrate in the Diagnosis of Prostate Cancer,”The Prostate, 1999, vol. 38, pp. 237-245.
Costello, L.C. et al., “The Intermediary Metabolism of the Prostate: A Key to Understanding the Pathogenesis and Progression of Prostate Malignancy,”Oncology, 2000, vol. 59, pp. 269-282.
Costello, L.C. et al., “Zinc causes a shift toward citrate at equilibrium of the m-aconitase reaction of prostate mitochondria,”Journal of Inorganic Biochemistry, 2000, vol. 78, pp. 161-165.
Duncan, L.M. et al., “Down-Regulation of the Novel GeneMelastatinCorrelates with Potential for Melanoma Metastasis,”Cancer Research, Apr. 1, 1998, vol. 58, pp. 1515-1520.
Fuessel, S. et al., “Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR,”International Journal of Oncology, 2003, vol. 23, pp. 221-228.
Hoffman, T. et al., “Transient receptor potential channels as molecular substrates of receptor-mediated cation entry,”J. Mol. Med., 2000, vol. 78, pp. 14-25.
Horoszewicz, J.S. et al., “Monoclonal Antibodies to a New Antigen Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients,”Anticancer Research, 1987, vol. 7, pp. 927-935.
Hunter, J.J. et al., “Chromosomal Localization and Genomic Characterization of the Mouse Melastatin Gene (Mlsn1),”Genomics, 1998, vol. 54, pp. 116-123.
International Search Report mailed on May 14, 2008, for International Application No. PCT/US07/04053 filed on Feb. 15, 2007, 1 page.
International Search Report mailed on May 4, 2009, for International Application No. PCT/US2008/083810 filed on Nov. 17, 2008, 2 pages.
John Hopkins Medicine, “BPH (Benign Prostatic Hyperplasia),”John Hopkins Medicine, Health Alerts, accessed on May 26, 2009, at <http://www.johnshopkinshealthalerts.com/symtpoms—remedies/benign—prostatic—hyperplasia/2207-1html>.
Kozolov, N.G. et al., “Reduction amination of 1-menthol by aliphatic nitriles,”Khimiya Prirodnykh Soedinenii, 1981, vol. 3, pp. 312-317, abstract only.
Mckemy, D.D. et al., “Identification of a cold receptor reveals a general role for TRP channels in thermosensation,”Nature, Mar. 7, 2002, vol. 416, pp. 52-58.
Murphy, G.P. et al., “Comparison of Prostate Specific Antigen, Prostate Specific Membrane Antigen, and LNCaP-Based Enzyme-Linked Immunosorbent Assays in Prostatic Cancer Patients and Patients With Benign Prostatic Enlargement,”The Prostate, 1995; vol. 26, pp. 164-168.
Murphy, G.P. et al., “Comparison of Serum PSMA, PSA Levels With Results of Cytogen-356 ProstaScint® Scanning in Prostatic Cancer Patients,”The Prostate, 1997, vol. 33, pp. 281-285.
Murphy, G.P. et al., “Infusion of Dendritic Cells Pulsed With HLA-A2-Specific Prostate-Specific Membrane Antigen Peptides: A Phase II Prostate Cancer Vaccine Trial Involving Patients With Hormone-Refractory Metastatic Disease,”The Prostate, 1999, vol. 38, pp. 73-78.
Nagamine, K. et al., “Molecular Cloning of a Novel Putative Ca2+Channel Protein (TRPC7) Highly Expressed in Brain,”Genomics, 1998, vol. 54, pp. 124-131.
Nealen, M.L. et al., “TRPM8 mRNA Is Expressed in a Subset of Cold-Responsive Trigeminal Neurons From Rat,”J. Neurophysiol, Jul. 2003, vol. 90, pp. 515-520.
Parker, S.L. et al., “Cancer Statistics, 1996,”CA Cancer J. Clin,. Jan./Feb. 1996, vol. 46, No. 1, pp. 5-27.
Peier, A.M. et al., “A TRP Channel that Senses Cold Stimuli and Menthol,”Cell, Mar. 8, 2002, vol. 108, pp. 705-715.
Reid, G. et al., “A Cold- And menthol-activated current in rat dorsal root ganglion neurones: properties and role in cold transduction,”Journal of Physiology, 2002, vol. 545.2, pp. 595- 614.
Rochon, Y.P. et al., “Western Blot Assay for Prostate-Specific Membrane Antigen in Serum of Prostate Cancer Patients,”The Prostate, 1994, vol. 25, pp. 219-223.
Swierzewski, S.J., III., “Urologic Emergencies: Acute Urinary Retention, Risk Factors, Causes, Treatment,” Jun. 10, 1998, accessed on May 26, 2009, at: <http://www.urologychannel.com/emergencies/acute.shtml>.
Tsavaler, L. et al., “Trp-p8, a Novel Prostate-specific Gene, Is Up-Regu
Duncan David F.
Moreno Ofir
Natarajan Sateesh
Dendreon Corporation
Fierro Alicia L
Saeed Kamal A
Townsend and Townsend / and Crew LLP
LandOfFree
Small-molecule modulators of TRP-p8 activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small-molecule modulators of TRP-p8 activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small-molecule modulators of TRP-p8 activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157800